Medicago, a Canadian company that operates a vaccine plant in Durham, announced Monday that it has been awarded a contract from the Department of Defense that allows it to bid on manufacturing contracts in the future.
The award could result in more work for the Durham plant, which employs more than 55 people.
"This contract is important as Medicago is now listed as a company meeting all of DARPA's rigorous technical requirements," said Mike Wanner, Medicago's executive vice president of operations, in a statement.
"This fits Medicago's revenue-generation model nicely as we can leverage our cost-effective commercial production facility in North Carolina to bid for production orders when they are issued by the U.S. government."
Medicago has already completed a $21 million federal contract to test a high-speed, high-volume production method for pandemic flu vaccine.